Page last updated: 2024-12-04

barbital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,5-diethylbarbituric acid : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2294
CHEMBL ID444
CHEBI ID31252
SCHEMBL ID43818
MeSH IDM0002175

Synonyms (95)

Synonym
barbituric acid, 5,5-diethyl-
57-44-3
uronal
hypnogene
barbituric acid,5-diethyl-
wln: t6vmvmv fhj f2 f2
verolettin
diethylbarbituric acid
nsc31352
vesperal
veronal
veroletten
sedeval
deba
barbital ,
5,5-diethylbarbituric acid
diethylbarbitone
malonal
diemal
barbitone
dormonal
2,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl-
diethylmalonylurea
ethylbarbital
nsc-31352
CHEBI:31252 ,
diethylmalonyl urea
OPREA1_012884
barbital, bioxtra, >=99.0% (t)
2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl-
inchi=1/c8h12n2o3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4h2,1-2h3,(h2,9,10,11,12,13
5,5-diethylpyrimidine-2,4,6(1h,3h,5h)-trione
barbitonum
barbitale [dcit]
nsc 31352
diemalum
einecs 200-331-2
ai3-02727
barbitalum [inn-latin]
kyselina 5,5-diethylbarbiturova [czech]
ccris 7420
brn 0163999
diethyl-barbituric acid
barbital (van)
dea no. 2145
NCGC00159419-02
NCGC00159419-03
DB01483
barbital (jp17/inn)
D01740
barbital (tn)
OPREA1_497227
CHEMBL444
5,5-diethyl-1,3-diazinane-2,4,6-trione
NCGC00159419-04
tox21_111650
dtxcid802643
cas-57-44-3
dtxsid5022643 ,
pharmakon1600-01900040
nsc759567
nsc-759567
barbital [inn:ban:jan:nf]
unii-5wz53ene2p
kyselina 5,5-diethylbarbiturova
5wz53ene2p ,
5-24-09-00137 (beilstein handbook reference)
barbitalum
barbitale
barbital [jan]
barbital [mart.]
barbital [vandf]
barbital [mi]
barbital [ep impurity]
barbital [ep monograph]
barbital [who-dd]
barbital [inn]
5,5-diethyl-pyrimidine-2,4,6-trione
EPITOPE ID:117124
AKOS015903028
5,5-diethyl-2,4,6(1h,3h,5h)-pyrimidinetrione
CCG-214014
SCHEMBL43818
tox21_111650_1
W-105467
AB00443731_03
barbital, european pharmacopoeia (ep) reference standard
sr-01000872752
SR-01000872752-1
barbital 1.0 mg/ml in methanol
barbital 0.1 mg/ml in methanol
SBI-0207064.P001
Q412409
BRD-K83359602-001-01-5
barbital, 1mg/ml in methanol

Research Excerpts

Overview

Barbital is a hypnotic agent that has been intensely studied for many decades. Barbital buffer is an effective long-acting sedative-hypnotic.

ExcerptReferenceRelevance
"Barbital is a hypnotic agent that has been intensely studied for many decades. "( Crystal polymorphs of barbital: news about a classic polymorphic system.
Apperley, DC; Gelbrich, T; Griesser, UJ; Harris, RK; Zencirci, N, 2014
)
2.16
"Barbital buffer is an effective long-acting sedative-hypnotic and is widely available from the laboratory shelf."( A case of barbiturate poisoning with a readily-accessible laboratory reagent.
Rodichok, LD, 1992
)
1

Treatment

Oral barbital treatments consisting of average daily doses of 200 mg/kg with durations of 15-50 weeks have been used. Barbital treated rats were divided into convulsing and non-convulsing groups. Mice treated with barbital (0.1% in the drinking water) during 15 days showed a 63% increased endoplasmic reticulum mass.

ExcerptReferenceRelevance
"The barbital treatment induced a clear tolerance to the hexobarbital, which still could be detected on day 28 of abstinence."( The effects of atropine on the tolerance and the convulsions seen after withdrawal from forced barbital drinking in the rat.
Wahlström, G, 1978
)
0.96
"Oral barbital treatments consisting of average daily doses of 200 mg/kg with durations of 15-50 weeks have been used to induce functional tolerance and physical dependence. "( Some aspects of the changes induced by chronic barbital treatments in the male rat.
Wahlström, G,
)
0.9
"Barbital treated rats were divided into convulsing and non-convulsing groups."( Nerve growth factor (NGF) in rat brain following long-term barbital treatment: relation to convulsions and cognitive function.
Archer, T; Lärkfors, L; Wahlström, G, 1992
)
1.25
"Mice treated with barbital (0.1% in the drinking water) during 15 days showed a 63% increased endoplasmic reticulum mass. "( Increased carbon tetrachloride-stimulated chemiluminescence in the in situ liver of barbital-treated mice.
Boveris, A; Fraga, CG; Llesuy, SF, 1984
)
0.83
"Pretreatment with barbital induced aversion to the drug solution regardless the conditions of pretreatments mainly because the unpalatability of the drug solution and also the unpleasant effect of injected drug."( [Determination of the development of psychotic dependence to drugs in small animals. 4. Selective drinking of barbital and ethanol solutions by mice].
Kaneto, H; Kosaka, N, 1982
)
0.8

Toxicity

ExcerptReferenceRelevance
" In contrast, only DEHP and BBS induced toxic renal lesions."( The chronic hepatic or renal toxicity of di(2-ethylhexyl) phthalate, acetaminophen, sodium barbital, and phenobarbital in male B6C3F1 mice: autoradiographic, immunohistochemical, and biochemical evidence for levels of DNA synthesis not associated with car
Anderson, LM; Diwan, BA; Hagiwara, A; Lindsey, K; Ward, JM, 1988
)
0.5

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study aims to develop and validate a rapid, simple, and efficient bioanalytical method for the simultaneous quantification of phenobarbital and barbital in human whole blood using liquid-liquid extraction combined with direct analysis in real time (DART) and high-resolution mass spectrometry (HRMS)."( Rapid quantification of phenobarbital and barbital in human whole blood by liquid-liquid extraction combined with DART-orbitrap-HRMS.
Ke, S; Lian, R; Liang, C; Liang, J; Rao, Y; Wang, R; Zhang, Y, 2023
)
1.4

Bioavailability

ExcerptReferenceRelevance
" The barbital absorption rate constant in deficient animals increased compared to control values."( Effect of alpha tocopherol (vitamin E) deficiency on intestinal transport of passively absorbed drugs.
Meshali, MM; Nightingale, CH, 1976
)
0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The effect of a forced long-term barbital treatment (daily dosage about 200 mg/kg for 32 weeks) on cholinergic brain mechanisms was studied. The overall effect of chronic administration of barbital was right shift in the dose-response curve for levels of cGMP following acute injections. In long barbital dosing (36 days), the metabolite level of carbohydrate was almost recovered to the non-treated level.

ExcerptRelevanceReference
" The magnitude of the response was greater in tolerant animals, but no parallel shift in the dose-response curve was seen."( The effects of atropine on the tolerance and the convulsions seen after withdrawal from forced barbital drinking in the rat.
Wahlström, G, 1978
)
0.48
" The results obtained here demonstrate the possibility of an occurence of the majority of the analyzed substances as metastable polymorphic modifications in solid dosage forms."( IR analysis of crystalline samples of some urea derivatives.
Halkiewicz, J; Kaliszan, R,
)
0.13
"After "chronically equivalent" barbital and pentobarbital dosing for 5 weeks, treatments were abruptly stopped and the animals were carefully observed for signs of barbiturate withdrawal."( Physical dependence to barbital compared to pentobarbital. III. Withdrawal characteristics.
Boisse, NR; Okamoto, M, 1978
)
0.85
" The rate of barbiturate elimination after chronically equivalent pentobarbital dosing was reduced by barbital substitution or by first-order pentobarbital dose reduction, with the result that withdrawal signs became mild and appeared later (3 days postdrug)."( Physical dependence to barbital compared to pentobarbital. IV. Influence of elimination kinetics.
Boisse, NR; Okamoto, M, 1978
)
0.8
" Principal features of the complex results include: double peaks in the time course of convulsion thresholds (Pc); an early peak and a shoulder in the time course of pressures reversing anesthesia (Pa); far steeper dose-response curves for Pa than for Pc; selectively greater anticonvulsant effect for phenobarbital than for the other barbiturates; and enhancement of Pa with simultaneous depression of Pc by reserpine in phenobarbital-pretreated mice."( Interaction of central nervous system effects of high pressures with barbiturates.
Beaver, RW; Brauer, RW; Lahser, S, 1977
)
0.43
" In fact, the response to PB-type inducers in male or female Zucker rats is probably most clearly explained as a shift of the dose-response curve sharply to the right (decreased responsiveness, compared to F344/NCr or DA rats of the same sex)."( A markedly diminished pleiotropic response to phenobarbital and structurally-related xenobiotics in Zucker rats in comparison with F344/NCr or DA rats.
Devor, DE; Diwan, BA; Dragnev, KH; Jones, CR; Lubet, RA; Miller, MS; Nims, RW; Rice, JM; Ward, JM, 1992
)
0.54
") prolonged B-induced sleeping time, but its dose-response relationship was not clearly observed."( N,N'-diallylbarbital potentiation of drug-induced sleep and motor incoordination.
Ho, IK; Tateoka, Y; Watanabe, K; Yamamoto, I, 1986
)
0.65
" Dose-response curves for the convulsive effect of pentylenetetrazol obtained at the peak of the withdrawal signs shifted greatly to the left in alcohol withdrawn animals but less in barbital withdrawn animals."( Differentiation of alcohol and barbital physical dependence.
Kaneda, H; Kaneto, H; Kawatani, S, 1986
)
0.75
" Withdrawal of barbital induced a significant leftward displacement of the dose-response curves obtained for the convulsive effects of strychnine, picrotoxin and 3-mercaptopropionic acid."( Central nervous system supersensitivity and withdrawal from long-term treatment with barbital.
Palermo-Neto, J; Sandoval, MR, 1985
)
0.85
" The overall effect of chronic administration of barbital was right shift in the dose-response curve for levels of cGMP following acute injections of barbital."( The effects of chronic oral administration of barbital on cerebellar cyclic GMP.
Lane, SJ; Morgan, WW, 1984
)
0.78
" The controls were comprised of naive rats (G-VI) and naive rats dosed in the same manner as the dependent rats."( Participant of serotonin turnover rate in the brain on barbital withdrawal convulsion.
Hiramori, T; Nakao, K; Tagashira, E; Urano, T; Yanaura, S, 1982
)
0.51
" The "low" level chronic dosing merely prolonged the time required to develop physical dependence of severity comparable to that produced by shorter durations of "high" level chronic dosing."( Physical dependence produced by long duration, low dose chronic barbital treatment.
Hinman, DJ; Okamoto, M, 1984
)
0.51
" Only the animals dosed with barbital exhibited severe withdrawal signs such as spontaneous withdrawal convulsions."( Effects of propranolol on barbital dependence formation and withdrawal signs.
Hiramori, T; Nakao, K; Tagashira, E; Urano, T; Yanaura, S, 1983
)
0.86
" In long barbital dosing (36 days), however, the metabolite level of carbohydrate was almost recovered to the non-treated level."( Biochemical aspects of experimental barbital dependence II: Effect on glycometabolism.
Kakuno, K; Nakao, K; Tagashira, E; Yanaura, S, 1983
)
0.96
"The effect of a forced long-term barbital treatment (daily dosage about 200 mg/kg for 32 weeks) on cholinergic brain mechanisms was studied on days 53 and 81 - 83 after withdrawal."( Changes in cholinergic function in rat brain late in abstinence after chronic barbital treatment.
Nordberg, A; Wahlström, G, 1981
)
0.77
" Furthermore, initiation-promotion experiments demonstrated a strong correlation between the dose-response of cell proliferation and the incidence of preneoplastic and neoplastic lesions."( Cell proliferation and renal carcinogenesis.
Short, BG, 1993
)
0.29
" From dose-response curves a dose of 4 mg/kg body weight of uranyl nitrate or cisplatin was chosen to produce acute renal failure in animals for pharmacokinetic study of barbital."( A comparative study of uranyl nitrate and cisplatin-induced renal failure in rat.
Mahmood, I; Waters, DH,
)
0.33
" In the test of physical dependence-producing potential with the drug-admixed food method in rats, vigabatrin and diazepam were given to rats mixed with food for 28 days in an increasing dosage schedule, followed by feeding a drug-free diet to observe withdrawal signs for 7 days."( Drug dependence study on vigabatrin in rhesus monkeys and rats.
Takada, K; Yanagita, T, 1997
)
0.3
" Although the appropriate selection of mouse strains and drug dosage levels has to be considered, these results suggest that the PLNA may be an appropriate screening system for prediction of the allergic or autoimmunity-inducing potentials of low-molecular-weight drugs."( Mouse popliteal lymph node assay for assessment of allergic and autoimmunity-inducing potentials of low-molecular-weight drugs.
Iwaki, Y; Kamimura, Y; Kuninishi, Y; Maki, E; Nakamura, K; Nishida, H; Shinkai, K; Suzuki, R; Takahashi, K; Takahashi, M; Tsutsui, N; Vohr, HW, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency0.07760.002541.796015,848.9004AID1347395
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency27.54040.01237.983543.2770AID1645841
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency15.84890.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID167610Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID38914Negative log of molar concentration (-log ED50) required to reduce cell division by 50% in Arbacia egg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1130945Inhibition of Arbacia egg cell division1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID1130943Octanol-water partition coefficient, log P of nonionized form of compound1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1768729Lipophilicity, logP of compound by shake flask method2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1145372Induction of hypnotic activity in rabbit1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID169097Negative log of molar concentration (-log C) required to produce 50% inhibition of oxygen (oxygen uptake) on rat brain respiration in vitro1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID1130940Retention index of the compound by HPLC method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1145374Induction of hypnotic activity in rat1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID1130944Hypnotic activity in rabbit1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1768730Relative lipophilicity of the compound in methanol assessed as retardation factor by reversed-phase TLC analysis2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,283)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901141 (88.93)18.7374
1990's77 (6.00)18.2507
2000's37 (2.88)29.6817
2010's18 (1.40)24.3611
2020's10 (0.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 95.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index95.78 (24.57)
Research Supply Index7.26 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index176.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (95.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (0.49%)5.53%
Reviews12 (0.85%)6.00%
Case Studies11 (0.78%)4.05%
Observational0 (0.00%)0.25%
Other1,388 (97.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]